vTv Therapeutics Inc. (NASDAQ:VTVT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday.

According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “

Other research analysts also recently issued reports about the company. HC Wainwright set a $13.00 price target on vTv Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 4th. Canaccord Genuity reaffirmed a “buy” rating and issued a $15.00 price target on shares of vTv Therapeutics in a research report on Friday, August 4th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $14.45.

vTv Therapeutics (VTVT) opened at 5.30 on Friday. vTv Therapeutics has a 1-year low of $4.65 and a 1-year high of $7.50. The stock’s 50 day moving average price is $5.45 and its 200 day moving average price is $5.78. The stock’s market capitalization is $51.37 million.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.41) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.02. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.19 million. Equities research analysts forecast that vTv Therapeutics will post ($1.06) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “vTv Therapeutics Inc. (VTVT) Downgraded by Zacks Investment Research to “Hold”” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/15/vtv-therapeutics-inc-vtvt-downgraded-by-zacks-investment-research-to-hold.html.

In other vTv Therapeutics news, major shareholder Ronald O. Perelman purchased 20,000 shares of the company’s stock in a transaction on Tuesday, August 22nd. The shares were bought at an average cost of $4.57 per share, with a total value of $91,400.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Ronald O. Perelman purchased 85,000 shares of the company’s stock in a transaction on Friday, August 11th. The stock was acquired at an average cost of $4.13 per share, for a total transaction of $351,050.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 165,000 shares of company stock worth $728,150. Company insiders own 0.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp increased its position in vTv Therapeutics by 6.1% in the 1st quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,305 shares during the period. State Street Corp increased its position in vTv Therapeutics by 2.1% in the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock worth $486,000 after buying an additional 1,976 shares during the period. Renaissance Technologies LLC increased its position in vTv Therapeutics by 4.8% in the 1st quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock worth $418,000 after buying an additional 2,900 shares during the period. Sphera Funds Management LTD. increased its position in vTv Therapeutics by 50.0% in the 1st quarter. Sphera Funds Management LTD. now owns 300,000 shares of the biotechnology company’s stock worth $1,965,000 after buying an additional 100,000 shares during the period. Finally, Ameriprise Financial Inc. increased its position in vTv Therapeutics by 62.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock worth $1,313,000 after buying an additional 101,850 shares during the period. 11.05% of the stock is currently owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.